Engineers Gate Manager’s BioXcel Therapeutics BTAI Stock Holding History

Engineers Gate Manager’s Portfolio BTAI Stock Details BTAI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-12,303	Closed	-$19.7K	–	2201
2025 Q4	$19.7K	Buy	+12,303	New	+$25.4K	﹤0.01%	2030
2025 Q1	–	Sell	-749	Closed	-$4.48K	–	2183
2024 Q4	$4.48K	Buy	+749	New	+$6.26K	﹤0.01%	2177
2024 Q3	–	Sell	-632	Closed	-$12.9K	–	2125
2024 Q2	$12.9K	Buy	+632	New	+$21.2K	﹤0.01%	1867
2024 Q1	–	Sell	-777	Closed	-$36.7K	–	1934
2023 Q4	$36.7K	Sell	777 -615	-44%	-$34.2K	﹤0.01%	1872
2023 Q3	$56.3K	Buy	+1,392	New	+$141K	﹤0.01%	1649
2021 Q3	–	Sell	-478	Closed	-$222K	–	1661
2021 Q2	$222K	Buy	+478	New	+$261K	0.01%	1338
2021 Q1	–	Sell	-324	Closed	-$240K	–	1829
2020 Q4	$240K	Buy	+324	New	+$252K	0.01%	1421

Other funds holding BTAI

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

OCM

Oaktree Capital Management Los Angeles, California $6.56B AUM 42.97% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Jones Financial Companies Des Peres, Missouri $208B AUM 16.12% 1-Year Est. Return

Man Group London, United Kingdom $55.1B AUM 24.23% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

VFT

Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM

Engineers Gate Manager's BTAI Position: Q1 2026 in Review

Engineers Gate Manager sold out of BioXcel Therapeutics (BTAI) in Q1 2026, closing a stake of 12,303 shares — an estimated $19.7K sold.

Engineers Gate Manager first reported a position in BTAI in Q4 2020 and held it in 7 quarters. The position peaked at $240K in Q4 2020. 40 funds tracked by Wall St. Rank hold BTAI as of Q1 2026.

Engineers Gate Manager reported no remaining BioXcel Therapeutics position as of Q1 2026 after selling out during the quarter.
Engineers Gate Manager sold 12,303 BioXcel Therapeutics shares in Q1 2026, an estimated $19.7K.
Engineers Gate Manager first reported a position in BioXcel Therapeutics in Q4 2020 and held it in 7 quarters.
Engineers Gate Manager's BioXcel Therapeutics position peaked at $240K in Q4 2020.
40 funds tracked by Wall St. Rank held BioXcel Therapeutics as of Q1 2026.

Based on Engineers Gate Manager's 13F filing for Q1 2026, filed 15 May 2026.